Next-Gen Diagnostics and Companion Diagnostics
Conventional biomarkers fail to capture the complexity of the immune response, contributing to high clinical trial attrition. MyImmune delivers the solution: an AI-driven Software as a Medical Device (SaMD) platform that deciphers the adaptive immune system to create predictive diagnostics with unparalleled precision.
Our proprietary algorithms generalize individual BCR/TCR repertoires into powerful, universal immune signatures. This enables the rapid development of high-fidelity diagnostics and companion diagnostics (CDx) across oncology, autoimmune disorders, and infectious diseases.
A New Benchmark in Diagnostic Performance
Validate your diagnostic strategy with statistically rigorous, externally benchmarked performance. Our platform achieves a mean ROC AUC of 0.99 in multi-disease classification across 15 indications, including pancreatic cancer, lupus, and NSCLC.
In head-to-head comparisons against the academic state-of-the-art, MyImmune delivers superior accuracy while reducing analytical costs by over 50%. By leveraging TCR sequencing data alone, our platform provides a definitive strategic advantage, enabling you to de-risk clinical programs and accelerate your diagnostic pipeline.